TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertensionAllschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee. The updated recommendations now list TRYVIO as a therapy that may be added for adults with difficult-to-control hypertension, including resistant hypertension. TRYVIO is the first systemic hypertension treatment to target a new pathway in over 30 years and the only new medicine to be included in the updated guidelines.
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in HypertensionAllschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of "Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertension1. The publication reports preplanned analyses of the efficacy, tolerability and safety of aprocitentan – Idorsia’s once-daily, orally active, dual endothelin receptor antagonist – in the subgroup of African American patients enrolled in the Phase 3 PRECISION study2 in patients with confirmed resistant hypertension. Aprocitentan, when added to a combination of at least three antihypertensive drugs (four in more than 50% of patients), produced clinically meaningful and sustained blood pressure reductions.1 Aprocitentan also markedly decreased proteinuria in the patients with proteinuria at baseline.1 As reported by the authors, aprocitentan was safe and well tolerated, even in those Black patients with chronic kidney disease.1
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirementAllschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on March 17, 2025), has now approved the updated label for TRYVIO™ (aprocitentan). TRYVIO is Idorsia’s dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination with other antihypertensives to lower blood pressure in patients who are not adequately controlled on other drugs. The FDA determined that a REMS was no longer necessary to ensure the benefits of TRYVIO outweigh the risk of embryo-fetal toxicity and that labeling is sufficient for conveying the safety information.
On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder Allschwil, Switzerland – March 17, 2023On World Sleep Day, Idorsia Ltd (SIX: IDIA) highlights the publication of a first-of-its-kind report by RAND Europe on the economic and societal impact of chronic insomnia disorder,† “The Societal and Economic Burden of Insomnia in Adults: An International Study”. Idorsia commissioned RAND Europe, an independent, not-for-profit policy research organization, to help fill some of the knowledge gaps associated with understanding the financial burden of chronic insomnia disorder and to deliver new peer-reviewed research into the impacts of insomnia.
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertensionAllschwil, Switzerland – December 20, 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension.
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS DrugsAllschwil, Switzerland – December 12, 2022Idorsia Ltd (SIX: IDIA) today announced the publication of “Long-term safety and tolerability of daridorexant in patients with insomnia disorder” in CNS Drugs1. The publication reports the results from the 40-week safety extension study with daridorexant in patients with insomnia disorder, which found that treatment with daridorexant, taken every night for up to 12 months, was well tolerated, consistent with the 12-week study findings as published by Mignot, E., et al. Lancet Neurol. 2022;21:125–39.
